Improvement of the green fluorescent protein reporter system in Leishmania spp. for the in vitro and in vivo screening of antileishmanial drugs

Acta Tropica

Volumn 122, Issue 1, 2012, Pages 36-45

  Pulido, Sergio A ^a   Muñoz, Diana L ^a   Restrepo, Adriana M ^a   Mesa, Carol V ^a   Alzate, Juan F ^a   Vélez, Iván D ^a   Robledo, Sara M ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Drug testing; Flow cytometry; GFP; Leishmaniasis; Recombination; Reporter gene; Transfection

Indexed keywords

ANTILEISHMANIAL AGENT; ENHANCED GREEN FLUORESCENT PROTEIN; RNA 18S;

BIOASSAY; DISEASE TREATMENT; DISEASE VECTOR; DRUG DEVELOPMENT; FLOW CYTOMETRY; GENE EXPRESSION; INFECTIVITY; LEISHMANIASIS; PROTEIN; RECOMBINATION; VIRULENCE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CHROMOSOME; CONTROLLED STUDY; DRUG SCREENING; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETIC MANIPULATION; GENETIC STABILITY; GENETIC TRANSFECTION; HOMOLOGOUS RECOMBINATION; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA; LEISHMANIA PANAMENSIS; LEISHMANIASIS; NONHUMAN; OPEN READING FRAME; PARASITE VIRULENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REPORTER GENE; SENSITIVITY AND SPECIFICITY; SYRIAN HAMSTER;

ANIMALS; ANTIPROTOZOAL AGENTS; CRICETINAE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FLOW CYTOMETRY; GENE EXPRESSION; GENES, REPORTER; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; LEISHMANIA; LEISHMANIASIS; MESOCRICETUS; MICROSCOPY, FLUORESCENCE; RECOMBINANT PROTEINS; STAINING AND LABELING;

CRICETINAE;

EID: 84857116769     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2011.11.015     Document Type: Article

References (29)

1. Ashutosh, Gupta S., Ramesh, Sundar S., Goyal N. Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening. Antimicrob. Agents Chemother. 2005, 49:3776-3783.
2. Beverley, S., 2001. US Patent application publication.
3. Bolhassani A., Taheri T., Taslimi Y., Zamanilui S., Zahedifard F., Seyed N., Torkashvand F., Vaziri B., Rafati S. Fluorescent Leishmania species: development of stable GFP expression and its application for in vitro and in vivo studies. Exp. Parasitol. 2011, 127:637-645.
4. Buckner F.S., Wilson A.J. Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages. Am. J. Trop. Med. Hyg. 2005, 72:600-605.
5. Chan M.M., Bulinski J.C., Chang K.P., Fong D. A microplate assay for Leishmania amazonensis promastigotes expressing multimeric green fluorescent protein. Parasitol. Res. 2003, 89:266-271.
6. Croft S.L., Seifert K., Yardley V. Current scenario of drug development for leishmaniasis. Indian J. Med. Res. 2006, 123:399-410.
7. Croft S.L., Yardley V., Kendrick H. Drug sensitivity of Leishmania species: some unresolved problems. Trans. R. Soc. Trop. Med. Hyg. 2002, 96:127-129.
8. Dube A., Singh N., Sundar S., Singh N. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol. Res. 2005, 96:216-223.
9. Finney D.J. Statistical Method in Biological Assay 1978, Academic Press, London, 508 p.
10. Hommel M., Jaffe C.L., Travi B., Milon G. Experimental models for leishmaniasis and for testing anti-leishmanial vaccines. Ann. Trop. Med. Parasitol. 1995, 89:55-73.
11. Hoyer C., Zander D., Fleischer S., Schilhabel M., Kroener M., Platzer M., Clos J.A. Leishmania donovani gene that confers accelerated recovery from stationary phase growth arrest. Int. J. Parasitol. 2004, 34:803-811.
12. Kamau S.W., Grimm F., Hehl A.B. Expression of green fluorescent protein as a marker for effects of antileishmanial compounds in vitro. Antimicrob. Agents Chemother. 2001, 45:3654-3656.
13. Lang T., Goyard S., Lebastard M., Milon G. Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice. Cell. Microbiol. 2005, 7:383-392.
14. Misslitz A., Mottram J.C., Overath P., Aebischer T. Targeted integration into a rRNA locus results in uniform and high level expression of transgenes in Leishmania amastigotes. Mol. Biochem. Parasitol. 2000, 107:251-261.
15. Okuno T., Goto Y., Matsumoto Y., Otsuka H., Matsumoto Y. Applications of recombinant Leishmania amazonensis expressing egfp or the beta-galactosidase gene for drug screening and histopathological analysis. Exp. Anim. 2003, 52:109-118.
16. Papadopoulou B., Dumas C. Parameters controlling the rate of gene targeting frequency in the protozoan parasite Leishmania. Nucleic Acids Res. 1997, 25:4278-4286.
17. Rey J.A., Travi B.L., Valencia A.Z., Saravia N.G. Infectivity of the subspecies of the Leishmania braziliensis complex in vivo and in vitro. Am. J. Trop. Med. Hyg. 1990, 43:623-631.
18. Rico E., Alzate J.F., Arias A.A., Moreno D., Clos J., Gago F., Moreno I., Domínguez M., Jiménez-Ruiz A. Leishmania infantum expresses a mitochondrial nuclease homologous to EndoG that migrates to the nucleus in response to an apoptotic stimulus. Mol. Biochem. Parasitol. 2009, 163:28-38.
19. Robledo S.M., Valencia A.Z., Saravia N.G. Sensitivity to glucantime of Leishmania Viannia isolated from patients prior to treatment. J. Parasitol. 1999, 85:360-366.
20. Roy G., Dumas C., Sereno D., Wu Y., Singh A.K., Tremblay M.J., Ouellette M., Olivier M., Papadopoulou B. Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol. Biochem. Parasitol. 2000, 110:195-206.
21. Sacks D.L., Perkins P.V. Identification of an infective stage of Leishmania promastigotes. Science 1984, 223:1417-1419.
22. Sacks D.L., Saraiva E.M., Rowton E., Turco S.J., Pimenta P.F. The role of the lipophosphoglycan of Leishmania in vector competence. Parasitology 1994, 108:55-62.
23. Sereno D., Cordeiro da Silva A., Mathieu-Daude F., Ouaissi A. Advances and perspectives in Leishmania cell based drug-screening procedures. Parasitol. Int. 2007, 56:3-7.
24. Sereno D., Roy G., Lemesre J.L., Papadopoulou B., Ouellette M. DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening. Antimicrob. Agents Chemother. 2001, 45:1168-1173.
25. Simmons D., Seed B. Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells. J. Immunol. 1988, 141:2797-2800.
26. Singh N., Dube A. Short report: fluorescent Leishmania: application to anti-leishmanial drug testing. Am. J. Trop. Med. Hyg. 2004, 71:400-402.
27. Singh N., Gupta R., Jaiswal A.K., Sundar S., Dube A. Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening. J. Antimicrob. Chemother. 2009, 64:370-374.
28. Varela M.R.E., Muñoz D.L., Robledo S.M., Kolli B.K., Dutta S., Chang K.P., Muskus C. Leishmania (Viannia) panamensis: an in vitro assay using the expression of GFP for screening of antileishmanial drug. Exp. Parasitol. 2009, 122:134-139.
29. WHO Technical report series; no. 949. Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March, 2010.